Ocular Antioxidants for AMD Prevention in Refractive Errors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively prevent, treat, or delay the onset of age-related macular degeneration (AMD) in individuals with hyperopia, presbyopia, or astigmatism, as they do not adequately address the increased risk of AMD associated with these ocular disorders, which can lead to significant vision loss and blindness.
Innovation Solution
Administration of a therapeutically effective amount of ocular antioxidants, including macular pigments like lutein and zeaxanthin, along with vitamins A, C, E, beta-carotene, zinc, copper, and other antioxidants, to subjects at risk for or already experiencing hyperopia, presbyopia, or astigmatism, to reduce the risk and progression of AMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatment methods are used for hyperopia, presbyopia, or astigmatism, then vision correction is achieved, but the increased risk of AMD progression is not addressed
Solution Approach 1:
The patent introduces macular pigments (lutein, zeaxanthin, meso-zeaxanthin) as intermediary substances that selectively filter blue light wavelengths before they reach the retina. These pigments act as a protective mediator between the harmful blue light and the vulnerable retinal tissues, reducing oxidative stress and preventing AMD progression in patients with hyperopia, presbyopia, or astigmatism
Solution Approach 2:
The patent changes the chemical composition parameters of the ocular tissues by supplementing with specific antioxidants and macular pigments. This alters the light-absorbing and antioxidant properties of the macula, enhancing its ability to protect against blue light damage and free radical injury, thereby improving AMD prevention efficacy
2Reliability
If ocular antioxidants are administered to patients with hyperopia, presbyopia, or astigmatism, then AMD risk is reduced, but treatment complexity increases
Solution Approach 1:
The patent employs a multi-functional antioxidant formulation that simultaneously addresses multiple ocular health concerns: blue light filtration, free radical scavenging, oxidative stress reduction, and macular pigment optimization. This single comprehensive treatment regimen replaces multiple separate interventions, simplifying the overall treatment approach while maintaining high AMD prevention efficacy
Solution Approach 2:
The patent combines multiple protective agents (macular pigments, vitamins C and E, zinc, copper, selenium) into a unified therapeutic composition. This merging of various antioxidants and nutrients into one integrated treatment protocol reduces the complexity of administering multiple separate supplements while providing synergistic protection against AMD
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The supplementation with ocular antioxidants effectively reduces the risk and progression of AMD by mitigating blue light-induced damage to retinal tissues, improving visual acuity, and maintaining higher macular pigment optical density (MPOD) levels, thereby delaying the onset or progression of AMD in individuals with hyperopia, presbyopia, or astigmatism.
Implementation Method 1
mitigating blue light-induced damage to retinal tissues
Implementation Method 2
administration to subjects having or at risk for having hyperopia, presbyopia or astigmatism with a composition having a therapeutically effective amount of ocular antioxidants
Data Source
AI summary
A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).